Literature DB >> 34105518

Morphology Matters: A Critical Reappraisal of the Clinical Relevance of Morphologic Criteria From the 2019 WHO Classification in a Large Colorectal Cancer Cohort Comprising 1004 Cases.

Moritz Jesinghaus1,2,3, Maxime Schmitt1, Corinna Lang1, Marianne Reiser1, Alexander Scheiter4, Björn Konukiewitz1, Katja Steiger1, Miguel Silva5, Markus Tschurtschenthaler5,3, Sebastian Lange5, Sebastian Foersch6, Karl F Becker1,7, Dieter Saur5,3, Helmut Friess8, Kathrin Halfter9, Jutta Engel9, Melanie Boxberg1, Nicole Pfarr1, Dirk Wilhelm8, Wilko Weichert1,2,10.   

Abstract

The 2019 World Health Organization (WHO) classification of colorectal carcinoma (CRC) profoundly reclassified CRC subtypes and introduces tumor budding as a second major grading criterion, while condensing conventional grade into a 2-tiered system. So far it remains largely unexplored how these parameters interact with each other and whether they truly have an independent impact on patient prognosis. We reclassified a large single-center cohort of 1004 CRCs spanning 2 decades for adjusted WHO grade (low vs. high), tumor budding (Bd1/Bd2/Bd3), and CRC subtype (adenocarcinoma not otherwise specified, micropapillary, mucinous, serrated, medullary, adenoma-like, signet-ring cell, mixed adenoneuroendocrine carcinoma/neuroendocrine carcinoma, undifferentiated) according to the criteria of the 2019 WHO classification. We investigated the interaction of these parameters, their connection to stage/microsatellite status, and their significance for patient survival in the different subgroups. Specific subtypes other than adenocarcinoma not otherwise specified represented one third of all CRCs and were unevenly distributed throughout stage and microsatellite subgroups. Subtypes, WHO grade and tumor budding profoundly impacted all survival parameters (P<0.001 for all analyses), with CRC subtypes and tumor budding-but not WHO grade-being stage-independent prognosticators for all survival comparisons. WHO grade had very limited prognostic value in CRC subtypes, while tumor budding retained its strong prognostic impact in most scenarios. Accurate delineation of CRC subtypes introduced in the 2019 WHO classification provides strong stage-independent prognostic information, arguing that they should be considered in pathology reports and in clinical trials. Of the morphology-based grading schemes included in the 2019 WHO, tumor budding outperforms WHO grade.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 34105518     DOI: 10.1097/PAS.0000000000001692

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

1.  Grading of endocervical adenocarcinoma: a novel prognostic system based on tumor budding and cell cluster size.

Authors:  Haiyan Shi; Lei Ye; Weiguo Lu; Bingjian Lu
Journal:  Mod Pathol       Date:  2021-09-30       Impact factor: 7.842

2.  Bridging the Species Gap: Morphological and Molecular Comparison of Feline and Human Intestinal Carcinomas.

Authors:  Tanja Groll; Franziska Schopf; Daniela Denk; Carolin Mogler; Ulrike Schwittlick; Heike Aupperle-Lellbach; Sabrina Rim Jahan Sarker; Nicole Pfarr; Wilko Weichert; Kaspar Matiasek; Moritz Jesinghaus; Katja Steiger
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

3.  Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification.

Authors:  Björn Konukiewitz; Maxime Schmitt; Miguel Silva; Junika Pohl; Corinna Lang; Katja Steiger; Kathrin Halfter; Jutta Engel; Anna Melissa Schlitter; Melanie Boxberg; Nicole Pfarr; Dirk Wilhelm; Sebastian Foersch; Markus Tschurtschenthaler; Wilko Weichert; Moritz Jesinghaus
Journal:  Br J Cancer       Date:  2021-10-06       Impact factor: 7.640

4.  Novel Criteria for Intratumoral Budding with Prognostic Relevance for Colon Cancer and Its Histological Subtypes.

Authors:  Pantea Pour Farid; Markus Eckstein; Susanne Merkel; Robert Grützmann; Arndt Hartmann; Volker Bruns; Michaela Benz; Regine Schneider-Stock; Carol I Geppert
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

5.  Mixed adenoneuroendocrine carcinoma of the non-ampullary duodenum with mismatch repair deficiency: a rare case report.

Authors:  Yumi Nozawa; Kazuyuki Ishida; Niki Maiko; Atsuko Takada-Owada; Masato Onozaki; Mina Takaoka; Kinichi Matsuyama; Yuhki Sakuraoka; Yoshimasa Nakazato; Keiichi Kubota
Journal:  Med Mol Morphol       Date:  2022-05-20       Impact factor: 2.070

6.  pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas-proposal for a new pT3a/pT3b subclassification.

Authors:  Sebastian Foersch; Corinna Lang-Schwarz; Markus Eckstein; Carol Geppert; Maxime Schmitt; Björn Konukiewitz; Tanja Groll; Felix Schicktanz; Jutta Engel; Moritz Gleitsmann; Christina C Westhoff; Nadine Frickel; Anne-Sophie Litmeyer; Albert Grass; Paul Jank; Sebastian Lange; Markus Tschurtschenthaler; Dirk Wilhelm; Wilfried Roth; Michael Vieth; Carsten Denkert; Iris Nagtegaal; Wilko Weichert; Moritz Jesinghaus
Journal:  Br J Cancer       Date:  2022-07-21       Impact factor: 9.075

7.  Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups.

Authors:  Maxime Schmitt; Miguel Silva; Björn Konukiewitz; Corinna Lang; Katja Steiger; Kathrin Halfter; Jutta Engel; Paul Jank; Nicole Pfarr; Dirk Wilhelm; Sebastian Foersch; Carsten Denkert; Markus Tschurtschenthaler; Wilko Weichert; Moritz Jesinghaus
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.